This call will feature a discussion of the current standard of care and the potential of bezuclastinib and elenestinib being developed by Cogent Bio and Blueprint Medicines as treatments for indolent systemic mastocytosis. There will be a particular focus on the data from the Phase 2 SUMMIT clinical trial of bezuclastinib and the Phase 2/3 HARBOR clinical trial of elenestinib recently presented at ASH 2023.